ArticleScientific reports2025
Comparison of intravaginal and interstitial brachytherapy in cervical cancer after inadvertent hysterectomy: a retrospective study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of this study was to compare intravaginal brachytherapy (IVBT) with interstitial brachytherapy (ISBT) in patients presenting with residual or recurrent disease after inadvertent hysterectomy for cervical cancer. Records of consecutive patients with cervical cancer, registered in the Radiotherapy Outpatient Department (RTOPD) between March 2018 and March 2021, who had inadvertent hysterectomy followed by external beam radiotherapy (EBRT) and IVBT (n = 15) or ISBT (n = 15) were analyzed retrospectively. All the patients received a dose of 45-50 Gy/25 fractions in 5 weeks by EBRT with concurrent cisplatin. A dose of 6 Gy/fraction/week for two consecutive weeks was prescribed at 5 mm from the surface of the vaginal cylinder in the IVBT arm. Patients in the ISBT arm were treated with 6 Gy/fraction for four fractions over two days with Martinez Universal Perineal Interstitial Template (MUPIT). Overall survival (OS) and disease-free survival (DFS) were the primary endpoints. Acute and late toxicities were the secondary endpoints. Median follow-up (FU) was 24.3 months and 32.8 months in the IVBT and ISBT arms respectively. Most of the patients failed within 12-18 months after brachytherapy. The 3-year OS for IVBT and ISBT arms were 54% and 93% respectively (p = 0.011). The 3-year DFS for IVBT and ISBT arms were 42% and 93% respectively(p = 0.023). Both the arms had similar acute & late toxicities. ISBT had significantly better survival outcomes in terms of OS, and DFS with similar toxicity as compared to IVBT in patients with residual or recurrent disease after inadvertent hysterectomy for cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.